文献速递膀胱癌与上尿路尿路上皮癌

NeoBLAST:肌层浸润性膀胱癌新辅助治疗后临床完全缓解者主动监测对比确定性膀胱治疗的试点随机对照试验方案

NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.
PubMed 文献 · Eur Urol Oncol · 2026-08-07

NeoBLAST是一项开放标签2/3期随机对照试验,纳入新辅助治疗后达临床完全缓解的可切除肌层浸润性膀胱癌患者,1:1随机接受主动监测或确定性膀胱治疗。2期主要终点为随机化可行性(≥25%,即72例中≥18例接受随机),3期主要终点为2年无转移生存,计划随机172例以10%非劣效界值评估主动监测的非劣效性。

要点

  • cCR由常规影像、循环肿瘤DNA、膀胱MRI及模板膀胱活检综合判定。
  • 2期可行性阈值:cCR患者随机接受度≥25%(72例中≥18例)。
  • 3期拟随机172例,以10%非劣效界值检验主动监测非劣效性。

核心结论

  • NeoBLAST旨在评估新辅助治疗后达cCR的肌层浸润性膀胱癌患者随机接受主动监测对比确定性膀胱治疗的可行性,并最终证明主动监测的非劣效性。

研究设计与样本

  • 开放标签2/3期随机对照试验,纳入可切除MIBC cT2-T4aN0M0且新辅助治疗后达cCR的患者,1:1随机至主动监测或确定性膀胱治疗。
  • 2期于2025年8月启动,计划入组2年,2027年扩展为多中心3期试验。

关键数值与推荐

  • 2期主要终点为随机化可行性,定义为cCR患者中≥25%(≥18/72)接受随机。
  • 3期主要终点为2年无转移生存,需随机172例cCR患者以10%为非劣效界值。
  • cCR由常规影像、循环肿瘤DNA、膀胱MRI和模板膀胱活检判定。

临床怎么用

  • 该试验若获阳性结果,可能支持在新辅助治疗后cCR的MIBC患者中以主动监测替代确定性膀胱治疗。

局限性

  • 存在可行性不足及随机后非预期交叉的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although many patients with muscle-invasive bladder cancer (MIBC) achieve a pathologic complete response (CR) following neoadjuvant therapy (NAT), subsequent definitive bladder treatment (DBT) - radical cystectomy (RC) or trimodal therapy (TMT) remain standard treatments. Preliminary evidence suggests that a subset of patients may avoid DBT, but a definitive randomized comparison has not been conducted. NeoBLAST aims to evaluate the feasibility of randomizing patients with MIBC who achieve a clinical CR (cCR) following NAT to active surveillance (AS) versus DBT and to ultimately demonstrate the non-inferiority of AS. This study is an open-label phase 2/3 randomized controlled trial. Patients with resectable MIBC cT2-T4aN0M0 who achieve a cCR after receiving NAT are randomized 1:1 to AS or DBT. cCR determined by conventional imaging, circulating tumor DNA, bladder MRI, and template bladder biopsy. NeoBLAST phase 2 opened in August 2025 with the plan to enrol for 2 years and expand to a multicenter phase 3 trial in 2027. The phase 2 primary endpoint is feasibility to randomize, defined as ≥25% (≥18 of 72) acceptance of randomization in patients with cCR. The phase 3 primary endpoint is metastasis-free survival at 2 years. To determine a non-inferiority margin of 10%, the trial will need to randomize 172 patients with cCR. This study has the potential to be practice-changing by establishing the non-inferiority of AS in a randomized setting, but carries a risk of poor feasibility and unintended cross over after randomization. FUNDING: Canadian Institutes of Health Research and the Vancouver Prostate Centre. ETHICS AND TRIAL REGISTRATION: University of British Columbia H23-02447, NCT06537154.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. St-Laurent MP, Eigl BJ, Tyldesley S, et al. NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol. Eur Urol Oncol. 2026. PMID: 42567733. doi:10.1016/j.euo.2026.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。